Literature DB >> 28529340

Vasculitis: A CLEAR argument for targeting complement in ANCA vasculitis.

Ralph Kettritz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28529340     DOI： 10.1038/nrneph.2017.69

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

1.  Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

Authors:  David R W Jayne; Annette N Bruchfeld; Lorraine Harper; Matthias Schaier; Michael C Venning; Patrick Hamilton; Volker Burst; Franziska Grundmann; Michel Jadoul; István Szombati; Vladimír Tesař; Mårten Segelmark; Antonia Potarca; Thomas J Schall; Pirow Bekker
Journal:  J Am Soc Nephrol       Date:  2017-04-11       Impact factor: 10.121

2.  Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies.

Authors:  Hong Xiao; Adrian Schreiber; Peter Heeringa; Ronald J Falk; J Charles Jennette
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

3.  C5a receptor (CD88) blockade protects against MPO-ANCA GN.

Authors:  Hong Xiao; Daniel J Dairaghi; Jay P Powers; Linda S Ertl; Trageen Baumgart; Yu Wang; Lisa C Seitz; Mark E T Penfold; Lin Gan; Peiqi Hu; Bao Lu; Norma P Gerard; Craig Gerard; Thomas J Schall; Juan C Jaen; Ronald J Falk; J Charles Jennette
Journal:  J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 10.121

4.  Neutrophil extracellular traps can activate alternative complement pathways.

Authors:  H Wang; C Wang; M-H Zhao; M Chen
Journal:  Clin Exp Immunol       Date:  2015-06-22       Impact factor: 4.330

5.  Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice.

Authors:  D Huugen; A van Esch; H Xiao; C J Peutz-Kootstra; W A Buurman; J W Cohen Tervaert; J C Jennette; P Heeringa
Journal:  Kidney Int       Date:  2007-02-14       Impact factor: 10.612

6.  Complement alternative pathway acts as a positive feedback amplification of neutrophil activation.

Authors:  Laurent Camous; Lubka Roumenina; Sylvain Bigot; Soumeya Brachemi; Véronique Frémeaux-Bacchi; Philippe Lesavre; Lise Halbwachs-Mecarelli
Journal:  Blood       Date:  2010-11-09       Impact factor: 22.113

7.  C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis.

Authors:  Adrian Schreiber; Hong Xiao; J Charles Jennette; Wolfgang Schneider; Friedrich C Luft; Ralph Kettritz
Journal:  J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 10.121

8.  Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Shen-Ju Gou; Jun Yuan; Min Chen; Feng Yu; Ming-Hui Zhao
Journal:  Kidney Int       Date:  2012-08-22       Impact factor: 10.612

9.  Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis.

Authors:  Su-Fang Chen; Feng-Mei Wang; Zhi-Ying Li; Feng Yu; Ming-Hui Zhao; Min Chen
Journal:  Arthritis Res Ther       Date:  2015-05-21       Impact factor: 5.156
  9 in total
  2 in total

Review 1.  Pediatric lupus nephritis.

Authors:  Sergio Veloso Brant Pinheiro; Raphael Figuiredo Dias; Rafaela Cabral Gonçalves Fabiano; Stanley de Almeida Araujo; Ana Cristina Simões E Silva
Journal:  J Bras Nefrol       Date:  2018-11-14

2.  Blockade of the kallikrein-kinin system reduces endothelial complement activation in vascular inflammation.

Authors:  Ingrid Lopatko Fagerström; Anne-Lie Ståhl; Maria Mossberg; Ramesh Tati; Ann-Charlotte Kristoffersson; Robin Kahn; Jean-Loup Bascands; Julie Klein; Joost P Schanstra; Mårten Segelmark; Diana Karpman
Journal:  EBioMedicine       Date:  2019-08-20       Impact factor: 8.143
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.